FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., Jan 15, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. LEQEMBI…

18th Asian Financial Forum wraps up successfully

- The 18th Asian Financial Forum (AFF) ended successfully today, drawing 3,600+ policymakers and business leaders from more than 50 countries and regions to discuss the latest developments in financial markets and investment opportunities- The event focused on how Hong Kong’s position as an international financial centre can be leveraged to navigate…

Honda Civic Hybrid Named 2025 North American Car of the Year, Making Civic the Most Honored Model in the History of the Award

Detroit, Michigan, Jan 13, 2025 - (JCN Newswire via SeaPRwire.com) - The new Honda Civic hybrid, the electrified variant of America's most popular compact car, has been honored with the prestigious 2025 North American Car of the Year™ award. It’s a record-setting fourth win for the Honda Civic, which has won more NACOTY…

Honda 2025 Motorsports Program Overview

TOKYO, Jan 10, 2025 - (JCN Newswire via SeaPRwire.com) - Honda announced its motorsports participation plans for the 2025 season.Since first entering the Isle of Man TT races in 1959, with company founder Soichiro Honda’s passion to become the world’s number one in technology, Honda has continued to participate in…

NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field

TOKYO, Jan 10, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding (MoU) for a joint marketing partnership to develop and expand artificial intelligence/deep learning (AI/DL)-based analytical platforms in the field of digital pathology(1). Through this partnership,…